Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds

Pharmaceutical companies are struggling to translate diagnostic intelligence into coordinated action that helps eligible patients reach appropriate treatment, according to new research from intelligence and engagement company, Diaceutics.

The survey of 125 US pharma leaders, 85% of whom hold Director-level positions or above, found that respondents increasingly recognize the importance of converting diagnosis into treatment, rating its significance to future commercial success at an average of 7.5 out of 10. More than half (56.8%) strongly agreed that diagnosis-to-treatment conversion is now as important as traditional brand promotion. Yet respondents rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10.

Other key findings included:

  • 48.8% of respondents rated identified patients not starting appropriate therapy as a significant challenge
  • Respondents rated their confidence in identifying eligible patients at 6.6 out of 10
  • Asked what prevents eligible patients receiving appropriate therapy, respondents identified access/reimbursement (51.2%), late testing (47.2%), failure to identify patients (44.8%) and test results not leading to treatment (36.8%)
  • Respondents rated their organizations' visibility across the patient journey, from testing through to treatment initiation, at just 5.4 out of 10

Together, the findings highlight the complexity of commercializing diagnostic-driven therapies, where successful treatment depends not only on identifying eligible patients but also on timely testing, appropriate clinical decisions and access to therapy.

The pharmaceutical industry has invested billions in developing increasingly precise therapies and sophisticated commercial capabilities, yet we're still struggling to connect the two. The industry is getting better at generating intelligence, but not necessarily at turning that intelligence into action when it matters. That's the contradiction the industry needs to confront and the challenge Diaceutics exists to help solve."

Ryan Keeling, CEO, Diaceutics

Industry leaders call for a new approach to commercialization

The survey findings informed Diaceutics' Precision for All Strategic Collaboration, a new initiative bringing together senior leaders from across the pharmaceutical industry to explore how to close the gap between scientific innovation and real-world patient impact.

An initial discussion involving representatives from several top 20 pharma organizations identified the need to integrate diagnostic planning much earlier in therapy development and commercialization, rather than addressing testing infrastructure and adoption challenges after launch.

Participants also called for greater industry collaboration to tackle shared challenges, including inconsistent testing practices, fragmented patient pathways and limited coordination between stakeholders. They highlighted the potential for AI and advanced analytics to help clinicians navigate increasingly complex diagnostic and treatment information, provided these technologies are supported by reliable data and integrated into clinical workflows.

A participant in the discussion, Andrew Witriol, Vice President, US Oncology Marketing, Bristol Myers Squibb, commented:

"We've made remarkable progress in precision medicine, particularly in oncology. But developing increasingly targeted therapies is only part of the equation. We also must identify the right patients, ensure the right testing happens at the right time and help translate innovation into clinical practice.

For me, that's where the next opportunity lies: not just advancing the science but improving how we translate that science into real-world impact. Data and AI can help us better understand where patients may be getting lost along the journey and where we can act differently - but ultimately, it takes collaboration across the healthcare ecosystem to close those gaps."

Through its ongoing Precision for All Strategic Collaboration, Diaceutics aims to bring more industry leaders together to identify practical solutions to shared challenges, including diagnostic readiness, coordination across the patient pathway and expanding access to diagnostic-driven therapies across a growing range of diseases.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Diaceutics PLC. (2026, November 18). Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds. News-Medical. Retrieved on November 18, 2026 from https://www.news-medical.net/news/20261118/Pharma-leaders-rate-ability-to-act-on-diagnostic-insights-just-5210-Diaceutics-survey-finds.aspx.

  • MLA

    Diaceutics PLC. "Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds". News-Medical. 18 November 2026. <https://www.news-medical.net/news/20261118/Pharma-leaders-rate-ability-to-act-on-diagnostic-insights-just-5210-Diaceutics-survey-finds.aspx>.

  • Chicago

    Diaceutics PLC. "Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds". News-Medical. https://www.news-medical.net/news/20261118/Pharma-leaders-rate-ability-to-act-on-diagnostic-insights-just-5210-Diaceutics-survey-finds.aspx. (accessed November 18, 2026).

  • Harvard

    Diaceutics PLC. 2026. Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds. News-Medical, viewed 18 November 2026, https://www.news-medical.net/news/20261118/Pharma-leaders-rate-ability-to-act-on-diagnostic-insights-just-5210-Diaceutics-survey-finds.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.